Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Breast Neoplasms

Triple Negative Breast Neoplasms

Recurrence

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Vinorelbine

Taxane

Tubulin Modulators

Antimitotic Agents

The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.

The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.

E7389 (Eribulin Mesylate)

Vinorelbine injection

This study is designed as an open-label randomized parallel two-arm multicenter efficacy, pharmacokinetics and safety study of intravenously administered eribulin versus intravenously administered vinorelbine in Chinese population. Eligible female subjects will have measurable disease according to RECIST 1.1 with the modification that chest x-ray cannot be used for assessment of disease.

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane

Eisai Co., Ltd.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	NCT02225470	HER2-Negative B... Triple Negative... Breast Cancer Cancer of Breas... Breast Tumors	E7389 (Eribulin... Vinorelbine inj...	18 Years - 70 Years	Eisai Inc.
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	NCT02225470	HER2-Negative B... Triple Negative... Breast Cancer Cancer of Breas... Breast Tumors	E7389 (Eribulin... Vinorelbine inj...	18 Years - 70 Years	Eisai Inc.

Spots Global Cancer Trial Database for e7389 (eribulin mesylate)